2.41

2.43% -0.06

Pre-market: 2.42 0.010 +0.41%

Organogenesis Holdings Inc (ORGO)

Overview News Price History Option Chain Financials Discussions Forecast

Organogenesis Holdings Inc stock is traded at $2.41, with a volume of 451.22K. It is down -2.43% in the last 24 hours and down -40.20% over the past month. Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Previous Close:

$2.47

Open:

$2.44

24h Volume:

451.22K

Relative Volume:

0.55

Market Cap:

$310.02M

Revenue:

$564.17M

Net Income/Loss:

$37.03M

P/E Ratio:

22.01

EPS:

0.1095

Net Cash Flow:

$-24.46M

1W Performance:

-4.74%

1M Performance:

-40.20%

6M Performance:

-50.82%

1Y Performance:

-55.54%

1-Day Range:

$2.385

$2.445

1-Week Range:

$2.305

$2.51

52-Week Range:

$2.305

$7.0771

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Name

Organogenesis Holdings Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

781-575-0775

Address

85 DAN ROAD, CANTON, MA

Employee

854

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ORGO's Discussions on Twitter

Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORGO Organogenesis Holdings Inc	2.41	310.02M	564.17M	37.03M	-24.46M	0.1095
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Lake Street	Buy
Feb-07-24	Initiated	Cantor Fitzgerald	Overweight
Jun-15-23	Initiated	Morgan Stanley	Equal-Weight
May-24-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Aug-10-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-10-20	Initiated	SVB Leerink	Outperform
Aug-26-19	Resumed	Credit Suisse	Outperform
May-02-19	Initiated	Credit Suisse	Outperform
Apr-17-19	Initiated	Oppenheimer	Outperform
Apr-11-19	Initiated	SunTrust	Buy

View All

Organogenesis Holdings Inc Stock (ORGO) Latest News

Mar 21, 2026

Income Plays: Is Organogenesis Holdings Inc benefiting from innovation trendsDividend Hike & Target Return Focused Picks - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Aug Summary: Is Organogenesis Holdings Inc impacted by rising ratesWatch List & AI Optimized Trading Strategy Guides - baoquankhu1.vn

Mar 20, 2026

Mar 17, 2026

Trading Recap: How does Organogenesis Holdings Inc correlate with Nasdaq2026 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn

Mar 17, 2026

Amniotic Membrane Market Is Booming Rapidly and Thriving by 2033 - openPR.com

Mar 17, 2026

Mar 16, 2026

Organogenesis $ORGO Shares Acquired by First Light Asset Management LLC - MarketBeat

Mar 16, 2026

Mar 12, 2026

Insider Buying: Organogenesis (NASDAQ:ORGO) Director Buys $13,400.00 in Stock - MarketBeat

Mar 12, 2026

Mar 11, 2026

Organogenesis director Leibowitz buys $13k in ORGO stock By Investing.com - Investing.com Canada

Mar 11, 2026

Insider Buying: Michael Driscoll Acquires Shares of Organogenesis Holdings Inc (ORGO) - GuruFocus

Mar 11, 2026

Organogenesis director Leibowitz buys $13k in ORGO stock - Investing.com

Mar 11, 2026

Director at Organogenesis (NASDAQ: ORGO) purchases 5,000 shares - Stock Titan

Mar 11, 2026

Organogenesis (NASDAQ:ORGO) Director Michael Joseph Driscoll Purchases 10,000 Shares of Stock - MarketBeat

Mar 11, 2026

Organogenesis (ORGO) director adds 10,000 shares in open-market purchase - Stock Titan

Mar 11, 2026

Mar 08, 2026

Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat

Mar 08, 2026

Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to “Buy” Rating - Defense World

Mar 08, 2026

Mar 06, 2026

Earnings Beat: Will Organogenesis Holdings Inc. stock gain from lower inflationWeekly Trade Report & Verified Technical Signals - Naître et grandir

Mar 06, 2026

Mar 03, 2026

Organogenesis (ORGO) VP uses 700 shares to cover tax withholding - Stock Titan

Mar 03, 2026

Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan

Mar 03, 2026

ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan

Mar 03, 2026

[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan

Mar 03, 2026

Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan

Mar 03, 2026

Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan

Mar 03, 2026

Mar 02, 2026

BTIG Research Cuts Organogenesis (NASDAQ:ORGO) Price Target to $8.00 - Defense World

Mar 02, 2026

Mar 01, 2026

Organogenesis Earnings Call: Record Highs Meet Policy Shock - TipRanks

Mar 01, 2026

Feb 28, 2026

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 28, 2026

ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI

Feb 28, 2026

Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat

Feb 28, 2026

Feb 27, 2026